Clinical Trial

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-11-22; most recent amendment 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2025-01-14
Trial Details
NCT Number NCT06704152
Lead Sponsor BlueSphere Bio, Inc
Conditions AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
Enrollment 38 participants
Start Date 2025-02-04
Primary Completion 2029-02 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-18